Local Infusion joins the QIVIGY(R) limited distribution network as the first Ambulatory Infusion Center. Local Infusion will expand its infusion offerings with the addition of QIVIGY(R)(Immune Globulin Intravenous, human-kthm) 10% liquid from Kedrion Biopharma NASHVILLE, Tenn. - Local Infusion, the fastest growing ambulatory infusion provider in the United States, today announced it is joining Kedrion Biopharma's limited distribution network for QIVIGY (immune globulin intravenous, human-kthm), a 10% intravenous immunoglobulin (IVIG) solution to treat adults with Primary Humoral Immunodeficiency (PI). QIVIGY was approved by the FDA in late 2025 and will be available for use in March 2026, giving patients a new option to replace deficient antibodies and reduce infection rates. Kedrion Biopharma selected Local Infusion for its unique capability to bring together infusion data, intelligent automation, and programmable care pathways to help patients get treated quicker, improve treatment adherence, and ultimately deliver better patient outcomes. "At Kedrion, our dedication to those affected by rare diseases drives everything we do," said Lynda Bowe, Vice President Corporate Accounts of Kedrion. "Working with Local Infusion, we are united in our goal to make QIVIGY available to more people living with Primary Humoral Immunodeficiency across more communities. Together, we can help ensure that patients get the therapies they need more conveniently and reliably." "Kedrion's decision to name Local Infusion as the first Ambulatory Infusion Center in its limited distribution network for QIVIGY is a testament to the high quality of care our patients receive," said Ashley Knapp, Co-Founder and Chief of Staff at Local Infusion. "Through this limited distribution network, patients receiving QIVIGY have a convenient, comfortable option that gets them to treatment faster." By joining the QIVIGY limited distribution network, Local Infusion continues to expand its patient-centered programs accelerating speed to treatment and patient outcomes in collaboration with manufacturers, healthcare providers, health systems, and payors nationwide. About Local Infusion Local Infusion is a leading health care and technology company dedicated to transforming the specialty infusion industry, because patients deserve better. By combining comfortable, patient-centered clinical care with a proprietary, AI-driven technology platform, Local Infusion accelerates access, simplifies workflows, and improves outcomes for everyone in the infusion journey - from patients and clinicians to health plans, health systems, employers, and pharma. With Local Infusion, every patient and every care team is fully supported, every step of the way. Learn more at www.mylocalinfusion.com. Local Infusion Media Contact Riley Steinmetz VP of Marketing [email protected]

Specialty Pharmacy news roundup: march 2026. The following are just a few of the many recent specialty pharmacy activities this past month. You can find even more news and insights by subscribing to AMI's Specialty Pharmacy Database. AOM Infusion, a leading provider of specialty infusion care and pharmacy services, announced that it has earned the Distinction in Immunoglobulin (Ig) Therapy from the Accreditation Commission for Health Care (ACHC) in collaboration with the Immunoglobulin National Society (IgNS). This distinction is designed to identify immunoglobulin therapy centers of excellence, and AOM is proud to be among the first infusion therapy providers nationwide to receive it. AOM Infusion announced it has joined Kedrion Biopharma's limited distribution network for QIVIGY, a new 10% immune globulin (Ig) liquid indicated for treatment of adults with Primary Humoral Immunodeficiency (PI). The addition of QIVIGY expands AOM's immune globulin portfolio and strengthens its ability to help patients and providers access innovative therapies for complex immune disorders. This announcement builds on AOM's recent collaboration with Kedrion for YIMMUGO, a 10% immune globulin liquid also indicated for the treatment of PI. CarepathRx announced a new statewide Ancillary Agreement with Humana Healthy Horizons in Ohio. This partnership significantly expands CarepathRx's reach, allowing the company to provide Home Infusion Therapy, Specialty Infusions, and Enteral Nutrition services to Medicaid members throughout the entire state. This collaboration reflects its ongoing commitment to delivering high-touch specialty pharmacy care exactly where patients need it most. Local Infusion, the fastest growing ambulatory infusion provider in the United States, announced it is joining Kedrion Biopharma's limited distribution network for QIVIGY (immune globulin intravenous, human-kthm), a 10% intravenous immunoglobulin (IVIG) solution to treat adults with Primary Humoral Immunodeficiency (PI). Lumicera Health Services, a leading specialty pharmacy solutions provider and Top 10 national specialty pharmacy, announced that it has earned URAC's Rare Disease Pharmacy Center of Excellence Certification. This premier, evidence-based certification recognizes specialty pharmacies demonstrating exceptional, high-touch care and advanced capabilities serving patients with rare and complex conditions. The designation builds on Lumicera's existing URAC Specialty Pharmacy Accreditation, further validating Lumicera's commitment to exceeding expectations for patients requiring specialized therapies and individualized support. Onco360, the nation's leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI (relacorilant), which is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. Transition Pharmacy, Regalo Health's direct-to-patient pharmacy, has relocated its primary fulfillment operations from Trevose, Pennsylvania, to a new 18,000-square-foot purpose-built facility at 100 Corporate Drive in Montgomeryville. The move expands capacity and strengthens its ability to deliver timely, high-quality care nationwide. Located in a well-connected regional logistics hub, the new facility supports more efficient shipping coordination and improved on-time delivery performance. The expanded space is designed for high-volume pharmacy operations with enhanced infrastructure. UVA Health has opened Pharmacy Central Services - a critical hub for UVA Health University Medical Center including UVA Health Children's; and UVA Health Culpeper, Haymarket, and Prince William Medical Centers in Northern Virginia. Continuing to support all three of its UVA Health strategic plan goals of expanding its excellence, cultivating healthy communities, and strengthening its foundation - Pharmacy Central Services widens its reach across Virginia, and to more than a dozen other states from Florida to Massachusetts.

/PRNewswire/ -- Tinsley Medical Practice Brokers is pleased to announce the successful sale of Carolina Neurology of Spartanburg, LLC to Local Infusion, a...